393 related articles for article (PubMed ID: 34207360)
21. Design and Synthesis of DDR1 Inhibitors with a Desired Pharmacophore Using Deep Generative Models.
Yoshimori A; Asawa Y; Kawasaki E; Tasaka T; Matsuda S; Sekikawa T; Tanabe S; Neya M; Natsugari H; Kanai C
ChemMedChem; 2021 Mar; 16(6):955-958. PubMed ID: 33289306
[TBL] [Abstract][Full Text] [Related]
22. Research progress of DDR1 inhibitors in the treatment of multiple human diseases.
Liu M; Zhang J; Li X; Wang Y
Eur J Med Chem; 2024 Mar; 268():116291. PubMed ID: 38452728
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of tumor-microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain.
Grither WR; Longmore GD
Proc Natl Acad Sci U S A; 2018 Aug; 115(33):E7786-E7794. PubMed ID: 30061414
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening.
Chen C; Deng J; Yu X; Wu F; Men K; Yang Q; Zhu Y; Liu X; Jiang Q
Mol Biosyst; 2016 Apr; 12(5):1540-51. PubMed ID: 26956955
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2.
Wang Z; Zhang Y; Pinkas DM; Fox AE; Luo J; Huang H; Cui S; Xiang Q; Xu T; Xun Q; Zhu D; Tu Z; Ren X; Brekken RA; Bullock AN; Liang G; Ding K; Lu X
J Med Chem; 2018 Sep; 61(17):7977-7990. PubMed ID: 30075624
[TBL] [Abstract][Full Text] [Related]
26. Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection.
Vella V; Malaguarnera R; Nicolosi ML; Morrione A; Belfiore A
Biochim Biophys Acta Mol Cell Res; 2019 Nov; 1866(11):118522. PubMed ID: 31394114
[TBL] [Abstract][Full Text] [Related]
27. Discovery of
Liu L; Zhao L; Yang L; Chai M; Liu Z; Ma N; Wang Y; Wu Q; Guo J; Zhou F; Huang W; Ren X; Wang J; Ding M; Wang Z; Ding K
J Med Chem; 2024 May; 67(10):8043-8059. PubMed ID: 38730324
[TBL] [Abstract][Full Text] [Related]
28. Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Li Y; Lu X; Ren X; Ding K
J Med Chem; 2015 Apr; 58(8):3287-301. PubMed ID: 25569119
[TBL] [Abstract][Full Text] [Related]
29. A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril.
Orgel JPRO; Madhurapantula RS
Biochim Biophys Acta Mol Cell Res; 2019 Nov; 1866(11):118478. PubMed ID: 31004686
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel (E)-1-methyl-9-(3-methylbenzylidene)-6,7,8,9-tetrahydropyrazolo[3,4-d]pyrido[1,2-a]pyrimidin-4(1H)-one as DDR2 kinase inhibitor: Synthesis, molecular docking, and anticancer properties.
Ruzi Z; Bozorov K; Nie L; Zhao J; Akber Aisa H
Bioorg Chem; 2023 Jun; 135():106506. PubMed ID: 37030105
[TBL] [Abstract][Full Text] [Related]
31. Discoidin Domain Receptors, DDR1b and DDR2, Promote Tumour Growth within Collagen but DDR1b Suppresses Experimental Lung Metastasis in HT1080 Xenografts.
Wasinski B; Sohail A; Bonfil RD; Kim S; Saliganan A; Polin L; Bouhamdan M; Kim HC; Prunotto M; Fridman R
Sci Rep; 2020 Feb; 10(1):2309. PubMed ID: 32047176
[TBL] [Abstract][Full Text] [Related]
32. The D2 period of collagen II contains a specific binding site for the human discoidin domain receptor, DDR2.
Leitinger B; Steplewski A; Fertala A
J Mol Biol; 2004 Dec; 344(4):993-1003. PubMed ID: 15544808
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.
Kim HG; Tan L; Weisberg EL; Liu F; Canning P; Choi HG; Ezell SA; Wu H; Zhao Z; Wang J; Mandinova A; Griffin JD; Bullock AN; Liu Q; Lee SW; Gray NS
ACS Chem Biol; 2013 Oct; 8(10):2145-50. PubMed ID: 23899692
[TBL] [Abstract][Full Text] [Related]
34. DDR1: A major player in renal diseases.
Dorison A; Chantziantoniou C
Cell Adh Migr; 2018; 12(4):299-304. PubMed ID: 29455614
[TBL] [Abstract][Full Text] [Related]
35. Recent Advances in the Role of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast and Ovarian Cancer.
Chen L; Kong X; Fang Y; Paunikar S; Wang X; Brown JAL; Bourke E; Li X; Wang J
Front Cell Dev Biol; 2021; 9():747314. PubMed ID: 34805157
[TBL] [Abstract][Full Text] [Related]
36. The collagen structure of C1q induces wound healing by engaging discoidin domain receptor 2.
Hayuningtyas RA; Han M; Choi S; Kwak MS; Park IH; Lee JH; Choi JE; Kim DK; Son M; Shin JS
Mol Med; 2021 Oct; 27(1):125. PubMed ID: 34602056
[TBL] [Abstract][Full Text] [Related]
37. Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma.
Berestjuk I; Lecacheur M; Carminati A; Diazzi S; Rovera C; Prod'homme V; Ohanna M; Popovic A; Mallavialle A; Larbret F; Pisano S; Audebert S; Passeron T; Gaggioli C; Girard CA; Deckert M; Tartare-Deckert S
EMBO Mol Med; 2022 Feb; 14(2):e11814. PubMed ID: 34957688
[TBL] [Abstract][Full Text] [Related]
38. Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery.
Kothiwale S; Borza CM; Lowe EW; Pozzi A; Meiler J
Drug Discov Today; 2015 Feb; 20(2):255-61. PubMed ID: 25284748
[TBL] [Abstract][Full Text] [Related]
39. Discoidin Domain Receptor 2: A New Target in Cancer.
Xu X; Yu T; Wang Z
Oncol Res Treat; 2022; 45(4):205-215. PubMed ID: 35073544
[TBL] [Abstract][Full Text] [Related]
40. What Makes a Kinase Promiscuous for Inhibitors?
Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
